Clinical Study
The Association of IL-12b Polymorphisms with Systemic Lupus Erythematosus in Chinese Han Population
Table 3
Association of IL-12b SNP rs6887695 with laboratory parameters in SLE patients*.
| | | Genotype frequency, no. (%) | Allele frequency, no. (%) | | SNP, population | No. of subjects | Major homozygote | Hetero-zygote | Minor homozygote | P | Major allele | Minor allele | P | OR (95% CI) |
| Genotype or allele | | GG | GC | CC | | G | C | | | Total cases | 297 | 107 | 153 | 37 | | 367 | 227 | | | Hematological disorders | | | | | | | | | | Positive | 187 | 63 | 98 | 26 | 0.429 | 224 | 150 | 0.216 |
1.24 (0.88–1.76) | Negative | 110 | 44 | 55 | 11 | 143 | 77 | Proteinuria | | | | | | | | | | ≥0.5 g/24 h | 101 | 35 | 52 | 14 | 0.851 | 122 | 80 | 0.617 |
1.09 (0.77–1.55) | 0.5 g/24 h | 196 | 72 | 101 | 23 | 245 | 147 | Antinuclear antibody | | | | | | | | | | 1 : 320 | 168 | 67 | 87 | 14 | 0.032 | 221 | 115 | 0.022 |
0.68 (0.49–0.95) | 1 : 320 | 129 | 40 | 66 | 23 | 146 | 112 | Anti-DNA | | | | | | | | | | Positive | 189 | 72 | 97 | 20 | 0.352 | 241 | 137 | 0.191 |
0.80 (0.57–1.12) | Negative | 108 | 35 | 56 | 17 | 126 | 90 | Anti-nRNP | | | | | | | | | | Positive | 81 | 31 | 41 | 9 | 0.846 | 103 | 59 | 0.581 |
0.90 (0.62–1.31) | Negative | 216 | 76 | 112 | 28 | 264 | 168 | Anti-Smith | | | | | | | | | | Positive | 68 | 24 | 37 | 7 | 0.783 | 85 | 51 | 0.845 |
0.96 (0.65–1.43) | Negative | 229 | 83 | 116 | 30 | 282 | 176 | Anti-Ro (SSA) | | | | | | | | | | Positive | 118 | 43 | 61 | 14 | 0.968 | 147 | 89 | 0.837 |
0.97 (0.69–1.35) | Negative | 179 | 64 | 92 | 23 | 220 | 138 | Anti-La (SSB) | | | | | | | | | | Positive | 72 | 25 | 38 | 9 | 0.963 | 88 | 56 | 0.848 |
1.04 (0.71–1.53) | Negative | 225 | 82 | 115 | 28 | 279 | 171 | C3 and C4 | | | | | | | | | | Decrease | 133 | 49 | 79 | 15 | 0.399 | 177 | 109 | 0.960 |
0.99 (0.71–1.38) | Normal | 164 | 58 | 74 | 22 | 190 | 118 |
|
|
*SNP: single-nucleotide polymorphism; SLE: systemic lupus erythematosus; OR: odds ratios; 95% CI: 95% confidence interval.
|